The effects of HIV-1 regulatory TAT protein expression on brain reward function, response to psychostimulants and delay-dependent memory in mice

Neuropharmacology

Volumn 109, Issue , 2016, Pages 205-215

  Kesby, James P ^a,b   Markou, Athina ^a   Semenova, Svetlana ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Anhedonia; Cognition; Dopamine; Methamphetamine; Serotonin

Indexed keywords

DOPAMINE; DOXYCYCLINE; METHAMPHETAMINE; NICOTINE; PSYCHOSTIMULANT AGENT; SEROTONIN; TRANSACTIVATOR PROTEIN; CENTRAL STIMULANT AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRACRANIAL SELF-STIMULATION TEST; LIMBIC SYSTEM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REWARD; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM; WORKING MEMORY; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; MEMORY; PHYSIOLOGY; REACTION TIME; TIME FACTOR; TRANSGENIC MOUSE;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENE PRODUCTS, TAT; HIV-1; MALE; MEMORY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; REACTION TIME; REWARD; TIME FACTORS;

EID: 84978536129     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2016.06.011     Document Type: Article

References (65)

1. Amitai, N., Semenova, S., Markou, A., Clozapine attenuates disruptions in response inhibition and task efficiency induced by repeated phencyclidine administration in the intracranial self-stimulation procedure. Eur. J. Pharmacol. 602 (2009), 78–84.
2. Arseniou, S., Arvaniti, A., Samakouri, M., HIV infection and depression. Psychiatry Clin. Neurosci. 68 (2014), 96–109.
3. Bansal, A.K., Mactutus, C.F., Nath, A., Maragos, W., Hauser, K.F., Booze, R.M., Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res. 879 (2000), 42–49.
4. Barnes, S.A., Der-Avakian, A., Markou, A., Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia. Eur. Neuropsychopharmacol. 24 (2014), 744–758.
5. Barreto, I.C.G., Viegas, P., Ziff, E.B., Konkiewitz, E.C., Animal models for depression associated with HIV-1 infection. J. Neuroimmune Pharm. 9 (2014), 195–208.
6. Berger, J.R., Kumar, M., Kumar, A., Fernandez, J.B., Levin, B., Cerebrospinal fluid dopamine in HIV-1 infection. Aids 8 (1994), 67–71.
7. Beyene, M., Carelli, R.M., Wightman, R.M., Cue-evoked dopamine release in the nucleus accumbens shell tracks reinforcer magnitude during intracranial self-stimulation. Neuroscience 169 (2010), 1682–1688.
8. Bocker, R., Estler, C.J., Maywald, M., Weber, D., Comparison of distribution of doxycycline in mice after oral and intravenous application measured by a high-performance liquid chromatographic method. Arzneimittel-Forschung 31 (1981), 2116–2117.
9. Carey, A.N., Liu, X., Mintzopoulos, D., Paris, J.J., McLaughlin, J.P., Kaufman, M.J., Conditional tat protein brain expression in the GT-tg bigenic mouse induces cerebral fractional anisotropy abnormalities. Curr. HIV Res. 13 (2015), 3–9.
10. Carey, A.N., Liu, X.X., Mintzopoulos, D., Paris, J.J., Muschamp, J.W., McLaughlin, J.P., Kaufman, M.J., Conditional Tat protein expression in the GT-tg bigenic mouse brain induces gray matter density reductions. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 43 (2013), 49–54.
11. Carey, A.N., Sypek, E.I., Singh, H.D., Kaufman, M.J., McLaughlin, J.P., Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. Behav. Brain Res. 229 (2012), 48–56.
12. Carlezon, W.A. Jr., Beguin, C., DiNieri, J.A., Baumann, M.H., Richards, M.R., Todtenkopf, M.S., Rothman, R.B., Ma, Z., Lee, D.Y., Cohen, B.M., Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J. Pharmacol. Exp. Ther. 316 (2006), 440–447.
13. Chang, L., Wang, G.J., Volkow, N.D., Ernst, T., Telang, F., Logan, J., Fowler, J.S., Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. NeuroImage 42 (2008), 869–878.
14. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008), 46–56.
15. Der-Avakian, A., Markou, A., The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 35 (2012), 68–77.
16. Der-Avakian, A., Mazei-Robison, M.S., Kesby, J.P., Nestler, E.J., Markou, A., Enduring deficits in brain reward function after chronic social defeat in rats: susceptibility, resilience, and antidepressant response. Biol. Psychiatry 76 (2014), 542–549.
17. Dunn, A.J., Swiergiel, A.H., de Beaurepaire, R., Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci. Biobehav Rev. 29 (2005), 891–909.
18. Ferris, M.J., Frederick-Duus, D., Fadel, J., Mactutus, C.F., Booze, R.M., The human immunodeficiency virus-1-associated protein, Tat1-86, impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study. Neuroscience 159 (2009), 1292–1299.
19. Ferris, M.J., Frederick-Duus, D., Fadel, J., Mactutus, C.F., Booze, R.M., In vivo microdialysis in awake, freely moving rats demonstrates HIV-1 tat-induced alterations in dopamine transmission. Synapse 63 (2009), 181–185.
20. Ferris, M.J., Mactutus, C.F., Booze, R.M., Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci. Biobehav. Rev. 32 (2008), 883–909.
21. Fowler, C.D., Tuesta, L., Kenny, P.J., Role of alpha 5* nicotinic acetylcholine receptors in the effects of acute and chronic nicotine treatment on brain reward function in mice. Psychopharmacology 229 (2013), 503–513.
22. Gerasimov, M.R., Franceschi, M., Volkow, N.D., Rice, O., Schiffer, W.K., Dewey, S.L., Synergistic interactions between nicotine and cocaine or methylphenidate depend on the dose of dopamine transporter inhibitor. Synapse 38 (2000), 432–437.
23. Gorry, P.R., Ong, C., Thorpe, J., Bannwarth, S., Thompson, K.A., Gatignol, A., Wesselingh, S.L., Purcell, D.F.J., Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and role in the pathogenesis of HIV-1-associated dementia. Curr. Hiv Res. 1 (2003), 463–473.
24. Hahn, Y.K., Podhaizer, E.M., Farris, S.P., Miles, M.F., Hauser, K.F., Knapp, P.E., Effects of chronic HIV-1 Tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and behavior. Brain Struct. Funct. 220 (2015), 605–623.
25. Harrison, A.A., Markou, A., Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors. J. Pharmacol. Exp. Ther. 297 (2001), 316–325.
26. Harrod, S.B., Mactutus, C.F., Fitting, S., Hasselrot, U., Booze, R.M., Intra-accumbal Tat(1-72) alters acute and sensitized responses to cocaine. Pharmacol. Biochem. Behav. 90 (2008), 723–729.
27. Heaton, R.K., Franklin, D.R., Ellis, R.J., McCutchan, J.A., Letendre, S.L., LeBlanc, S., Corkran, S.H., Duarte, N.A., Clifford, D.B., Woods, S.P., Collier, A.C., Marra, C.M., Morgello, S., Mindt, M.R., Taylor, M.J., Marcotte, T.D., Atkinson, J.H., Wolfson, T., Gelman, B.B., McArthur, J.C., Simpson, D.M., Abramson, I., Gamst, A., Fennema-Notestine, C., Jernigan, T.L., Wong, J., Grant, I., Charter, Grp H., HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J. Neurovirol. 17 (2011), 3–16.
28. Heaton, R.K., Grant, I., Butters, N., White, D.A., Kirson, D., Atkinson, J.H., McCutchan, J.A., Taylor, M.J., Kelly, M.D., Ellis, R.J., et al. The HNRC 500: neuropsychology of HIV infection at different disease stages. J. Int. Neuropsychol. Soc. 1 (1995), 231–251.
29. Heaton, R.K., Marcotte, T.D., Mindt, M.R., Sadek, J., Moore, D.J., Bentley, H., McCutchan, J.A., Reicks, C., Grant, I., The, H.G., The impact of HIV-associated neuropsychological impairment on everyday functioning. J. Int. Neuropsychol. Soc. 10 (2004), 317–331.
30. Hernandez, G., Trujillo-Pisanty, I., Cossette, M.P., Conover, K., Shizgal, P., Role of dopamine tone in the pursuit of brain stimulation reward. J. Neurosci. 32 (2012), 11032–11041.
31. Kaul, M., Lipton, S.A., Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr. HIV Res. 4 (2006), 307–318.
32. Kesby, J.P., Cui, X., Ko, P., McGrath, J.J., Burne, T.H., Eyles, D.W., Developmental vitamin D deficiency alters dopamine turnover in neonatal rat forebrain. Neurosci. Lett. 461 (2009), 155–158.
33. Kesby, J.P., Heaton, R.K., Young, J.W., Umlauf, A., Woods, S.P., Letendre, S.L., Markou, A., Grant, I., Semenova, S., Methamphetamine exposure combined with HIV-1 disease or gp120 expression: comparison of learning and executive functions in humans and mice. Neuropsychopharmacology 40 (2015), 1899–1909.
34. Kesby, J.P., Hubbard, D.T., Markou, A., Semenova, S., Expression of HIV gp120 protein increases sensitivity to the rewarding properties of methamphetamine in mice. Addict. Biol. 19 (2014), 593–605.
35. Kesby, J.P., Markou, A., Semenova, S., Effects of HIV/TAT protein expression and chronic selegiline treatment on spatial memory, reversal learning and neurotransmitter levels in mice. Behav. Brain Res. 311 (2016), 131–140.
36. Kim, B.O., Liu, Y., Ruan, Y.W., Xu, Z.C., Schantz, L., He, J.J., Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am. J. Pathol. 162 (2003), 1693–1707.
37. King, R.M., Vidrine, D.J., Danysh, H.E., Fletcher, F.E., McCurdy, S., Arduino, R.C., Gritz, E.R., Factors associated with nonadherence to antiretroviral therapy in HIV-positive smokers. Aids Patient Care STDS 26 (2012), 479–485.
38. Koob, G.F., Volkow, N.D., Neurocircuitry of addiction. Neuropsychopharmacology 35 (2010), 217–238.
39. Lawson, M.A., Kelley, K.W., Dantzer, R., Intracerebroventricular administration of HIV-1 Tat induces brain cytokine and indoleamine 2,3-dioxygenase expression: a possible mechanism for AIDS comorbid depression. Brain Behav. Immun. 25 (2011), 1569–1575.
40. Li, W.X., Li, G.H., Steiner, J., Nath, A., Role of tat protein in HIV neuropathogenesis. Neurotox. Res. 16 (2009), 205–220.
41. Loret, E.P., Darque, A., Jouve, E., Loret, E.A., Nicolino-Brunet, C., Morange, S., Castanier, E., Casanova, J., Caloustian, C., Bornet, C., Coussirou, J., Boussetta, J., Couallier, V., Blin, O., Dussol, B., Ravaux, I., Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial. Retrovirology, 13, 2016, 21.
42. Manji, H.K., Drevets, W.C., Charney, D.S., The cellular neurobiology of depression. Nat. Med. 7 (2001), 541–547.
43. McLaughlin, J.P., Ganno, M.L., Eans, S.O., Mizrachi, E., Paris, J.J., HIV-1 tat protein exposure potentiates ethanol reward and reinstates extinguished ethanol-conditioned place preference. Curr. HIV Res. 12 (2015), 415–423.
44. Mediouni, S., Marcondes, M.C.G., Miller, C., McLaughlin, J.P., Valente, S.T., The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders. Front. Microbiol., 6, 2015, 24.
45. Midde, N.M., Gomez, A.M., Harrod, S.B., Zhu, J., Genetically expressed HIV-1 viral proteins attenuate nicotine-induced behavioral sensitization and alter mesocorticolimbic ERK and CREB signaling in rats. Pharmacol. Biochem. Behav. 98 (2011), 587–597.
46. Midde, N.M., Gomez, A.M., Zhu, J., HIV-1 tat protein decreases dopamine transporter cell surface expression and vesicular monoamine Transporter-2 function in rat striatal synaptosomes. J. Neuroimmune Pharm. 7 (2012), 629–639.
47. Nemeth, C.L., Glasper, E.R., Harrell, C.S., Malviya, S.A., Otis, J.S., Neigh, G.N., Meloxicam blocks neuroinflammation, but not depressive-like behaviors, in HIV-1 transgenic female rats. Plos One, 9, 2014, 9.
48. Owesson-White, C.A., Cheer, J.F., Beyene, M., Carelli, R.M., Wightman, R.M., Dynamic changes in accumbens dopamine correlate with learning during intracranial self-stimulation. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 11957–11962.
49. Panee, J., Pang, X., Munsaka, S., Berry, M.J., Chang, L., Independent and Co-morbid HIV infection and meth use disorders on oxidative stress markers in the cerebrospinal fluid and depressive symptoms. J. Neuroimmune Pharm. 10 (2015), 111–121.
50. Paris, J.J., Carey, A.N., Shay, C.F., Gomes, S.M., He, J.J., McLaughlin, J.P., Effects of conditional central expression of HIV-1 tat protein to potentiate cocaine-mediated psychostimulation and reward among male mice. Neuropsychopharmacology 39 (2014), 380–388.
51. Paris, J.J., Fenwick, J., McLaughlin, J.P., Progesterone protects normative anxiety-like responding among ovariectomized female mice that conditionally express the HIV-1 regulatory protein, Tat, in the CNS. Horm. Behav. 65 (2014), 445–453.
52. Paris, J.J., Singh, H.D., Ganno, M.L., Jackson, P., McLaughlin, J.P., Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat. Psychopharmacology 231 (2014), 2349–2360.
53. Paxinos, G., Franklin, K., The Mouse Brain in Stereotaxic Coordinates. 2001, Academic Press, San Diego.
54. Pizzagalli, D.A., Jahn, A.L., O'Shea, J.P., Toward an objective characterization of an anhedonic phenotype: a signal detection approach. Biol. Psychiatry 57 (2005), 319–327.
55. Sadek, J.R., Vigil, O., Grant, I., Heaton, R.K., Grp, H., The impact of neuropsychological functioning and depressed mood on functional complaints in HIV-1 infection and methamphetamine dependence. J. Clin. Exp. Neuropsychol. 29 (2007), 266–276.
56. Stoker, A.K., Markou, A., The intracranial self-stimulation procedure provides quantitative measures of brain reward function. T Mood and Anxiety Related Phenotypes in Mice, 63, 2011, 307–331.
57. Stoker, A.K., Semenova, S., Markou, A., Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology 54 (2008), 1223–1232.
58. Tegger, M.K., Crane, H.M., Tapia, K.A., Uldall, K.K., Holte, S.E., Kitahata, M.M., The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. Aids Patient Care STDS 22 (2008), 233–243.
59. Theodore, S., Cass, W.A., Dwoskin, L.P., Maragos, W.F., HIV-1 protein Tat inhibits vesicular monoamine transporter-2 activity in rat striatum. Synapse 66 (2012), 755–757.
60. Volkow, N.D., Chang, L., Wang, G.J., Fowler, J.S., Franceschi, D., Sedler, M., Gatley, S.J., Miller, E., Hitzemann, R., Ding, Y.S., Logan, J., Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 21 (2001), 9414–9418.
61. Wallace, D.R., Dodson, S., Nath, A., Booze, R.M., Estrogen attenuates gp120-and tat(1-72)-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 59 (2006), 51–60.
62. Wang, G.J., Smith, L., Volkow, N.D., Telang, F., Logan, J., Tomasi, D., Wong, C.T., Hoffman, W., Jayne, M., Alia-Klein, N., Thanos, P., Fowler, J.S., Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol. Psychiatr. 17 (2012), 918–925.
63. Woolley, M.L., Ballard, T.M., Age-related impairments in operant DMTP performance in the PS2APP mouse, a transgenic mouse model of Alzheimer's disease. Behav. Brain Res. 161 (2005), 220–228.
64. Zhu, J., Mactutus, C.F., Wallace, D.R., Booze, R.M., HIV-1 Tat protein-induced rapid and reversible decrease in H-3 dopamine uptake: dissociation of H-3 dopamine uptake and H-3 2 beta-Carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes. J. Pharmacol. Exp. Ther. 329 (2009), 1071–1083.
65. Zhu, J., Midde, N.M., Gomez, A.M., Sun, W.L., Harrod, S.B., Intra-ventral tegmental area HIV-1 Tat(1-86) attenuates nicotine-mediated locomotor sensitization and alters mesocorticolimbic ERK and CREB signaling in rats. Front. Microbiol., 6, 2015, 17.